Kallistatin

Kallistatin is an endogenous serine protease inhibitor (serpin), also known as SERPINA4 or tissue kallikrein-binding protein. It is present in various human tissues including the liver, kidney, heart, and vasculature. Kallistatin exerts multiple biological effects such as vasodilation, anti-angiogenesis, anti-inflammatory activity, anti-tumor effects, and antioxidant properties[1][2][3][4]. Mechanistically, it inhibits tissue kallikrein activity via its active site and modulates several signaling pathways through its heparin-binding domain—blocking growth factors (e.g., VEGF), cytokines (e.g., TNF-α), and fibrotic mediators (e.g., TGF-β)[3][4][6]. Kallistatin has shown protective roles in animal models of hypertension, organ injury (heart and kidney), arthritis, sepsis, cancer progression/metastasis[4], and renal fibrosis[5]. Its levels are reduced in various disease states including liver disease/cirrhosis[1], chronic kidney disease[5], diabetes mellitus complications[4], inflammatory diseases[6], obesity-related conditions[4], and certain cancers. Circulating kallistatin is being investigated as a biomarker for these diseases. While not currently an approved pharmaceutical drug or marketed therapy itself,[3] recombinant forms or gene delivery approaches are under preclinical investigation for therapeutic use.

Other names

serpin A4tissue kallikrein-binding proteinSERPINA4SERPINA-4SERPINA 4